Nonstructural protein 2 (nsP2) of chikungunya virus (CHIKV) enhances protective immunity mediated by a CHIKV envelope protein expressing DNA vaccine

Viral Immunology

Volumn 26, Issue 1, 2013, Pages 75-83

  Bao, Huihui ^a   Ramanathan, Aarti A ^a   Kawalakar, Omkar ^a   Sundaram, Senthil G ^b   Tingey, Colleen ^a   Bian, Charoran B ^a   Muruganandam, Nagarajan ^b   Vijayachari, Paluru ^b   Sardesai, Niranjan Y ^c   Weiner, David B ^a   Ugen, Kenneth E ^d,e   Muthumani, Karuppiah ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^c Inovio Pharmaceuticals   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIKUNGUNYA ALPHAVIRUS ENVELOPE DNA VACCINE; DNA VACCINE; NONSTRUCTURAL PROTEIN 2; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CHIKUNGUNYA; CHIKUNGUNYA ALPHAVIRUS; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; MORBIDITY; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

ADJUVANTS, IMMUNOLOGIC; ALPHAVIRUS INFECTIONS; ANIMALS; CHIKUNGUNYA VIRUS; DISEASE MODELS, ANIMAL; FEMALE; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; VACCINES, DNA; VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84874050762     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2012.0061     Document Type: Article

References (37)

1. Sourisseau M, Schilte C, Casartelli N, et al., Characterization of reemerging chikungunya virus. PLoS Pathog, 2007;3:e89.
2. Reiter P, Fontenille D, and Paupy C. Aedes albopictus as an epidemic vector of chikungunya virus: Another emerging problem? Lancet Infect Dis 2006;6:463-464.
3. Reinert JF, Harbach RE, and Kitching IJ. Phylogeny and classification of Aedini (Diptera: Culicidae), based on morphological characters of all life stages. Zool J Linn Soc 2004;142:289-368.
4. Grivard P, Le Roux K, Laurent P, et al. Molecular and serological diagnosis of Chikungunya virus infection. Pathol Biol (Paris) 2007;55:490-494.
5. Thiboutot MM, Kannan S, Kawalekar OU, et al. Chikungunya: A potentially emerging epidemic? PLoS Negl Trop Dis 2010;4:e623.
6. Ross RW. The Newala epidemic. III. The virus: Isolation, pathogenic properties and relationship to the epidemic. J Hyg (Lond) 1956;54:177-191.
7. Kumar NP, Joseph R, Kamaraj T, and Jambulingam P. A226V mutation in virus during the 2007 chikungunya outbreak in Kerala, India. J Gen Virol 2008;89:1945-1948.
8. Manimunda SP, Sinigh SS, Sugunan AP, et al. Chikungunya fever, Andaman and Nicobar Islands, India. Emerg Infect Dis 2007;13:1259-1260.
9. Muthumani K, Lankarraman KM, Laddy DJ, et al. Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine 2008;26:5128-5134.
10. Sam IC, and AbuBakar S. Chikungunya virus infection. Med J Malaysia 2006;61:264-269.
11. Santhosh SR, Dash PK, Parida MM, et al. Comparative full genome analysis revealed E1: A226V shift in 2007 Indian Chikungunya virus isolates. Virus Res 2008;135:36-41.
12. Wang E, et al. Chimeric alphavirus vaccine candidates for chikungunya. Vaccine 2008;26:5030-5039.
13. Tiwari M, Parida M, Santhosh SR, et al. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 2009;27:2513-2522.
14. Blackburn SD, Shin H, Haining WN, et al., Coregulation of CD8 + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009;10: 29-37.
15. Akahata W, Yang ZY, Andersen H, et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med 2010;16: 334-338.
16. Fros JJ, Liu WJ, Prow NA, et al. Chikungunya virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT signaling. J Virol 2010;84:10877-10887.
17. Bourai M, Lucas-Hourani M, Gad HH, et al. Mapping of Chikungunya virus interactions with host proteins identified nsP2 as a highly connected viral component. J Virol 2012; 86:3121-3134.
18. Lang KA, Yan J, Draghia-Akli R, et al. Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine 2008;26:6225-6231.
19. Kim DY, Firth AE, Atasheva S, et al., Conservation of a packaging signal and the viral genome RNA packaging mechanism in alphavirus evolution. J Virol 2011;85:8022-8036.
20. Frolova EI, Gorchakov R, Pereboeva L, et al. Functional Sindbis virus replicative complexes are formed at the plasma membrane. J Virol 2010;84:11679-11695.
21. Mallilankaraman K, Shedlock DJ, Bao H, et al. A DNA vaccine against Chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis 2011;5:e928.
22. Yin J, et al., High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation. Vaccine, 2011;29:6763-6770.
23. Ng LF, Chow A, Sun YJ, et al. IL-1beta, IL-6, and RANTES as biomarkers of Chikungunya severity. PLoS ONE 2009; 4:e4261.
24. Bartholomay LC, waterhouse RM, Mayhew GF, et al. Pathogenomics of Culex quinquefasciatus and meta-analysis of infection responses to diverse pathogens. Science 2010;330: 88-90.
25. Enserink M. Infectious diseases. Massive outbreak draws fresh attention to little-known virus. Science 2006;311:1085.
26. Higgs S. The 2005-2006 Chikungunya epidemic in the Indian Ocean. Vector Borne Zoonotic Dis 2006;6:115-116.
27. Kutzler MA, and Weiner DB. DNA vaccines: Ready for prime time? Nat Rev Genet 2008;9:776-788.
28. Shedlock DJ, Talbott KT, Cress C, et al. A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge. Vaccine 2011;29:6755-6762.
29. Morrow MP, and Weiner DB. DNA drugs come of age. Sci Am 2010;303:48-53.
30. Kawalekar OU, Shedlock DJ, and Weiner DB. Current strategies and limitations of HIV vaccines. Curr Opin Investig Drugs 2010;11:192-202.
31. Boyer JD, Robinson TM, Kutzler MA, et al. Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc Natl Acad Sci USA 2007;104:18648-18653.
32. Laddy DJ, Yan J, Khan AS, et al., Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol 2009;83:4624-4630.
33. Broderick KE, Shen X, Soderholm J, et al. Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device. Gene Ther 2011; 18:258-265.
34. Zaharoff DA, Barr RC, Li CY, Yuan F. Electromobility of plasmid DNA in tumor tissues during electric fieldmediated gene delivery. Gene Ther 2002;9:1286-1290.
35. Babiuk S, Baca-Estrada ME, Foldvari M, et al. Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J Biotechnol 2004;110:1-10.
36. Yan J, et al. Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. Vaccine 2008;26:5210-5215.
37. Hirao LA, Wu L, Khan AS, et al. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 2008;26:440-448.